Header Image

Doru Paul (USA)

Doru Paul, MD, PhD

Assistant Professor of Medicine
Hofstra Northwell Health School of Medicine.
Attending Physician Hematology Oncology
Northwell Health Monter Cancer Center
450 Lakeville Road
Lake Success, New York, 11042
Tel. 1.516.734.8775
Fax. 516.734.8950
Email. pauldoru@gmail.com

YEAR DEGREE INSTITUTION FIELD OF STUDY
1987 Baccalaureate Diploma High School Number 1,

Bucharest, Romania

Mathematics-

Informatics

1993 M.D. Diploma Carol Davila

Faculty of Medicine

Bucharest, Romania

Medicine
1995 Clinical Oncology Diploma Faculty of Paris VII,

Paris, France

Clinical Oncology
1996 Chronobiology Diploma Faculty of Paris VI,

Paris, France

Chronobiology
1996  Masters Degree Diploma Faculty of Paris VI,

Paris, France

Biology of Aging
1999 Internal Medicine Residency

Diploma

Jacobi Hospital,

Bronx, NY

Internal Medicine
2002 Hematology-Oncology

Fellowship Diploma

Montefiore Hospital,

Bronx, NY

Hematology-

Oncology

2015 PhD Diploma

“summa cum laude”

Faculty of Medicine,

Craiova, Romania

Medicine

 

Licensure and Certifications

2015 PhD in Medicine, University of Medicine and Pharmacy, Craiova, Romania.
2014 Certified to practice Medical Oncology and Internal Medicine in Romania.
1999 Licensed to practice Medicine in the New York State. # 216174.
2005 Board Certified in Hospice and Palliative Care. (American Board of Hospice and Palliative Care).
2003 Board Certified in Hematology. (American Board of Internal Medicine).Recertified in 2013
2002 Board Certified in Medical Oncology. (American Board of Internal Medicine). Recertified in 2012.
1999 Board Certified in Internal Medicine. (American Board of Internal
Medicine). Recertified in 2009.
1996 Master Degree in the Biology of Aging, Paris, France.

Academic Appointments

current-7/2012 Assistant Professor of Medicine
Hofstra Northwell Health School of Medicine.

2/2012-7/2005 Assistant Professor of Clinical Medicine
Weill Medical College of Cornell University.

6/2005-7/2003 Instructor of Clinical Medicine
Weill Medical College of Cornell University

Other Professional Positions and Visiting Appointments

2012-2005 Director, Clinical Research, Lincoln Cancer Center, Lincoln Hospital.
NSABP and ECOG Principal Investigator.
2012-2003 Chairman of the Blood Utilization & Transfusion Committee.
2012-2002 Member of the Lincoln Hospital IRB.
2012-2006 Chairman of the Research Sub-Committee, Lincoln Hospital Cancer Center.
2006-2003 Coordinator, Palliative Care Team, Lincoln Hospital.
2004-2003 Interim Chief, Medical Oncology Department, Lincoln Hospital.

Hospital Appointments

Present-2/2012 Attending Hematology-Oncology, NSLIJHS Monter Cancer Center.

2/2012-9/2002 Attending Hematology-Oncology, Lincoln Hospital, Bronx, NewYork.

Memberships

Member of the American Society of Clinical Oncology (ASCO), American Scoiety of Hematology (ASH),American Association of cancer Research (AACR), the NewYork Academy of Science, Romanian Society of Medical Oncology (SNOMR), College of Doctors (Colegiul Medicilor).

At present I work as a Hematology and Medical Oncology Attending Specialist at the Monter Cancer Center, associated with North Shore-LIJ (NSLIJ) Hospital in Long Island, New York, part of the Northwell Group. In 2010 NSLIJ hospital received the prize for the best patient care in United States. Over the last 15 years, I have been the Principal Investigator (PI) or co-PI in more than 30 studies for both large national oncology research groups (i.e. CALGB, ECOG, NSABP) and for studies sponsored by private pharmaceutical companies (partial list below). In the past, I have also obtained INDs from the FDA for 2 studies initiated by myself. My main translational research interest is defining specific therapeutic targets or processes involved in cancer that can be used for the treatment of cancer patients. Over the last ten years I have been invited as a guest speaker on various aspects of Biological Targeted Agents at several oncology conferences in United States and Europe. In 2013, I was awarded a grant of the NSLIJ Cancer Institute for a novel Phase I study that uses FDG for the treatment of advanced cancers. The study is currently open for enrolment (clinicaltrials.gov). Also, in April 2017, I was the co-organizer of STOP CANCER, the first symposium of personalized oncology that took place in Bucharest, Romania. At the symposium there were 63 speakers, prominent clinicians and basic researchers from USA and Europe and was very well received.